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Progression From Paroxysmal
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Clinical Correlates and Prognosis
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Objectives We investigated clinical correlates of atrial fibrillation (AF) progression and evaluated the prognosis of patients
demonstrating AF progression in a large population.
Background Progression of paroxysmal AF to more sustained forms is frequently seen. However, not all patients will progress
to persistent AF.
Methods We included 1,219 patients with paroxysmal AF who participated in the Euro Heart Survey on AF and had a known
rhythm status at follow-up. Patients who experienced AF progression after 1 year of follow-up were identified.
Results Progression of AF occurred in 178 (15%) patients. Multivariate analysis showed that heart failure, age, previous
transient ischemic attack or stroke, chronic obstructive pulmonary disease, and hypertension were the only inde-
pendent predictors of AF progression. Using the regression coefficient as a benchmark, we calculated the HATCH
score. Nearly 50% of the patients with a HATCH score 5 progressed to persistent AF compared with only 6% of
the patients with a HATCH score of 0. During follow-up, patients with AF progression were more often admitted
to the hospital and had more major adverse cardiovascular events.
Conclusions A substantial number of patients progress to sustained AF within 1 year. The clinical outcome of these patients
regarding hospital admissions and major adverse cardiovascular events was worse compared with patients dem-
onstrating no AF progression. Factors known to cause atrial structural remodeling (age and underlying heart dis-
ease) were independent predictors of AF progression. The HATCH score may help to identify patients who are
likely to progress to sustained forms of AF in the near future. (J Am Coll Cardiol 2010;55:725–31) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.040t
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ctrial fibrillation (AF) is the most common sustained
ardiac arrhythmia in clinical practice. The arrhythmia is
ssociated with increased morbidity and mortality, mainly as
result of 2 complications: stroke and heart failure (1).
In clinical practice, one should distinguish between the
linical AF type (paroxysmal AF, episodes of the arrhythmia
hat terminate spontaneously) and persistent AF (episodes
hat are sustained longer than 7 days and are not self-
erminating) (2). The latter will affect the individual treat-
ent strategy for each patient. Important differences were
ound between the clinical subsets of AF (3). Underlying
eart disease occurs more frequently in patients with sus-
ained AF. Patients with paroxysmal AF are more often
rom the Cardiovascular Research Institute Maastricht, Maastricht University Med-
cal Centre, Maastricht, the Netherlands.f
Manuscript received August 13, 2009; revised manuscript received November 23,
009, accepted November 30, 2009.reated with antiarrhythmic drugs, whereas patients with
hronic AF receive more rate control therapy. In the
ARAF (Canadian Registry of Atrial Fibrillation) study,
nvestigators evaluated determinants of AF progression
4). The investigators found that underlying heart disease
nd age were independently associated with progression
f AF. The Euro Heart Survey (EHS) on AF presents a
See page 732
nique overview of AF management in a large group of
atients in several European countries. Nieuwlaat et al.
5) previously reported the influence of underlying heart
isease on the progression of AF in the EHS. However,
n this univariate analysis, no correction for possible
onfounders was performed, and the contribution of each
actor to AF progression was not studied.
A
v
p
A
w
c
c
e
m
c
c
w
1
A
p
w
r
t
p
1
w
c
I
e
c
n
t
m
r
a
f
p
b
d
1
(
t
h
T
t
i
S
S
I
a
(
s
t
f
c
a
c
w
r
t
e
c
T
A
d
r
f
i
f
s
u
e
t
p
r
i
h
a
d
i
p
C
P
(
O
s
R
T
w
f
b
p
o
t
H
f
m
726 de Vos et al. JACC Vol. 55, No. 8, 2010
Progression From Paroxysmal to Persistent AF February 23, 2010:725–31The present study is the largest
study to investigate the clinical
correlates of arrhythmia progres-
sion in patients with paroxysmal
AF. In addition, we evaluated the
prognosis of patients with AF pro-
gression and validated a risk strat-
ification rule to assess the proba-
bility of AF progression.
Methods
detailed description of the methods, data collection,
alidation, and the first results of the EHS on AF were
resented by Nieuwlaat et al. (6). In 2003 and 2004, 5,333
F patients were enrolled in this survey. These patients
ere enrolled at 182 hospitals in 35 different member
ountries of the European Society of Cardiology. Inclusion
riteria were age older than 18 years and AF on an
lectrocardiogram or Holter recording in the previous 12
onths or at the time of inclusion. Enrollment of
onsecutive patients took place at several sites within the
ardiology departments.
AF was classified into 5 categories. The clinical AF type
as first detected AF in 978 patients, paroxysmal AF in
,517 patients, persistent AF in 1,167 patients, permanent
F in 1,541 patients, and unknown type of AF in 130
atients. In the present study, only the records for patients
ith paroxysmal AF and first detected AF in whom sinus
hythm restored spontaneously or after pharmacological
reatment during admission were evaluated, leaving a study
opulation of 1,219 patients with a known rhythm status at
-year follow-up. We did not include patients who under-
ent electrical cardioversion to sinus rhythm because one
annot be sure that those patients have self-terminating AF.
n addition, we did not take persistent AF as a separate
ntity to evaluate progression to permanent AF because the
lassification permanent AF is physician driven and does
ot depend on the pathophysiology or clinical characteris-
ics of the arrhythmia and therefore precludes proper assess-
ent of progression (2).
In the EHS on AF, data were collected from medical
ecords and medical information systems or entered by the
ttending physician. Progression of AF was defined as
ollows: paroxysmal AF at baseline becoming persistent or
ermanent AF at 1-year follow-up or first detected AF at
aseline with spontaneous conversion to sinus rhythm
uring admission becoming persistent or permanent AF at
-year follow-up. We also determined the CHADS2 score
7). This acronym stands for congestive heart failure, hyper-
ension, age (75 years and older), diabetes mellitus, and a
istory of stroke/transient ischemic attack (TIA) (2 points).
his scoring system allows instant classification of the relative
hromboembolic risk in patients with AF and is incorporated
Abbreviations
and Acronyms
AF  atrial fibrillation
AUC  area under
the curve
COPD  chronic
obstructive pulmonary
disease
TIA  transient ischemic
attackn the latest guidelines on the management of AF. rtatistical analysis. Data analysis was performed with
PSS statistical software (version 15.0, SPSS Inc., Chicago,
llinois). Continuous variables are reported as mean  SD
nd categorical variables as observed number of patients
percentage). When comparing patients with AF progres-
ion and no AF progression regarding baseline characteris-
ics, treatment, or outcome, we used an independent t test
or continuous variables and the Fisher exact test for
ategorical variables. The p values resulting from these
nalyses are reported in Tables 1, 2, and 3. All baseline
haracteristics showing a significant univariate relationship
ith AF progression at follow-up were included in a logistic
egression model (heart failure in history, chronic obstruc-
ive pulmonary disease [COPD] in history, left atrial size on
chocardiogram, age, regular physical activity, hypertension,
oronary artery disease, valve disease, previous stroke or
IA, renal failure). We did not include the variables lone
F or CHADS2 score in the model because they were
erived from other variables included in the model. Model
eduction was performed by stepwise excluding variables
rom the model with a p value0.10. All variables that were
ndependently associated with AF progression were tested
or interactions. To develop a convenient score, the regres-
ion coefficients of the final logistic regression model were
sed to estimate the contribution of each variable to the risk
stimation of AF progression. This resulted in the attribu-
ion of 1 or 2 points for each variable included in the score.
The predictive accuracy of the known predictors of AF
rogression and the HATCH score was reported using a
eceiver-operator characteristic curve. To compare the discrim-
native power of the HATCH score (acronym stands for
ypertension, age [75 years and older], transient ischemic
ttack or stroke (2 points), chronic obstructive pulmonary
isease and heart failure (2 points); this scoring system allows
nstant classification of the risk of progression to persistent or
ermanent AF in patients with paroxysmal AF) and the
HADS2 score, we applied the Delong, Delong, Clarke-
earson method using Analyse-it 2.20 statistical software
Leeds, United Kingdom). All tests performed were 2 sided.
verall, a p value of 0.05 was considered to be statistically
ignificant.
esults
he age of the 1,219 patients included in the present study
as 64  13 years. Progression of AF to more sustained
orms occurred in 178 patients (15%). Table 1 shows the
aseline characteristics of patients with and without AF
rogression. Patients who experienced AF progression were
lder and performed less regular physical activity. In addi-
ion, these patients had more underlying heart disease.
ypertension, coronary artery disease, valve disease, heart
ailure, COPD, stroke or TIA, and renal failure occurred
ore frequently in patients with AF progression. This is
eflected by the higher mean CHADS2 score (1.9  1.3 vs.
1
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February 23, 2010:725–31 Progression From Paroxysmal to Persistent AF.2  1.1, p  0.001) and lower percentage of lone AF (8%
s. 19%, p  0.001) in patients with AF progression
ompared with patients whose AF remained paroxysmal
fter 1 year. No significant difference was found between the
ercentage of patients with diabetes demonstrating AF
Baseline CharacteristicsTable 1 Baseline Characteristics
A
n
Age (yrs)
Female
Body mass index (kg/m2)
Symptoms (admission)
Regular physical activity
Echocardiogram and electrocardiogram characteristics
Left atrial size on echo (mm)
Ventricular rate (when sinus rhythm)
Ventricular rate (when AF)
Type of AF
First detected
Paroxysmal 1
Underlying disease
Hypertension
Coronary artery disease
Diabetes mellitus
Valve disease
Heart failure
Chronic obstructive pulmonary disease
Hyperthyroidism
History of stroke or TIA
Malignancy
Peripheral vascular disease
Renal failure
Lone AF
CHADS2 score
Values are presented as n, n (%), or mean  SD.
AF  atrial fibrillation; TIA  transient ischemic attack.
Medication Use at BaselineTable 2 Medication Use at Baseline
All Patients
n 1,219
Oral anticoagulation 594 (50%)
Aspirin 437 (37%)
Beta-blocker 495 (42%)
Diltiazem 36 (3%)
Verapamil 60 (5%)
Digitalis 136 (11%)
Any antiarrhythmic drug 627 (52%)
Flecainide 89 (7%)
Disopyramide 6 (1%)
Propafenone 111 (9%)
Sotalol 145 (12%)
Amiodarone 288 (24%)
Angiotensin-converting enzyme inhibitor 518 (44%)
Angiotensin II receptor blocker 142 (12%)
Diuretics 428 (36%)Values are presented as n, n (%), or mean  SD.
AF  atrial fibrillation.rogression and patients who remained in sinus rhythm. On
he echocardiogram obtained at baseline, patients with AF
rogression had a larger left atrium.
Medication use at baseline is presented in Table 2.
nderstandably, all drugs associated with heart failure were
ents No AF Progression AF Progression p Value
9 1,041 (85%) 178 (15%)
13 63  13 68  11 0.001
43%) 439 (42%) 85 (49%) 0.165
4 27  4 28  5 0.246
75%) 773 (74%) 140 (79%) 0.261
34%) 370 (36%) 45 (25%) 0.010
8 43  8 45  8 0.001
15 70  15 72  19 0.195
30 109  31 110  30 0.712
14%) 140 (13%) 25 (14%)
86%) 901 (87%) 153 (86%)
62%) 626 (60%) 126 (71%) 0.007
32%) 321 (31%) 71 (40%) 0.024
15%) 148 (14%) 34 (19%) 0.110
19%) 188 (18%) 45 (25%) 0.030
21%) 181 (18%) 66 (38%) 0.001
11%) 104 (10%) 33 (19%) 0.002
5%) 52 (5%) 8 (5%) 0.853
9%) 77 (8%) 28 (16%) 0.001
5%) 47 (5%) 9 (5%) 0.699
6%) 58 (6%) 16 (9%) 0.089
5%) 41 (4%) 15 (9%) 0.018
17%) 189 (19%) 14 (8%) 0.001
1.2 1.2  1.1 1.9  1.3 0.001
No AF Progression AF Progression p Value
1,041 (85%) 178 (15%)
490 (49%) 104 (60%) 0.007
376 (37%) 61 (35%) 0.611
418 (41%) 77 (44%) 0.506
29 (3%) 7 (4%) 0.468
48 (5%) 12 (7%) 0.257
108 (11%) 28 (16%) 0.039
541 (52%) 86 (49%) 0.415
80 (8%) 9 (5%) 0.274
6 (1%) 0 0.601
101 (10%) 10 (6%) 0.090
128 (12%) 17 (10%) 0.379
237 (23%) 51 (29%) 0.086
411 (41%) 107 (62%) 0.001
130 (13%) 12 (7%) 0.023
339 (34%) 89 (51%) 0.001ll Pati
1,21
64 
524 (
27 
913 (
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Progression From Paroxysmal to Persistent AF February 23, 2010:725–31sed more frequently in patients with AF progression:
igitalis, angiotensin-converting enzyme inhibitors, and
iuretics. Furthermore, patients experiencing worsening
f their AF used more oral anticoagulation, which likely
s the result of a higher mean CHADS2 score in this
roup. Patients with AF progression used angiotensin II
eceptor blockers (7% vs. 13%, p  0.023) less frequently.
eta-blockers were prescribed in 56% of patients with
eart failure and in 65% of patients with coronary artery
isease.
During follow-up, in patients with AF progression, either
ersistent (46%) or permanent (54%) AF developed
Table 3). The patients with progression were more often
ymptomatic compared with patients without AF progres-
ion. Patients without AF progression had either first
etected AF (10%) or paroxysmal AF (83%), and nearly 7%
f the patients were considered cured by their physician.
Characteristics at 1-Year Follow-upTable 3 Characteristics at 1-Year Follow-up
All Patie
n 1,219
Symptoms 366 (32
Death 22 (2%
Type of AF
First detected 107 (9%
Paroxysmal 860 (71
Persistent 81 (7%
Permanent 97 (8%
Considered cured 74 (5%
Hospital admissions during 1 yr
Cardiovascular admissions 523 (53
Pharmacological cardioversion 255 (23
Number of pharmacological cardioversions 0.4  1
Electrical cardioversion 161 (15
Number of electrical cardioversions 0.2  0
Catheter ablation 61 (5%
Major adverse cardiovascular events
Coronary artery disease 72 (6%
Myocardial infarction 17 (1%
Unstable angina 44 (4%
Ischemic stroke or TIA 31 (3%
Ischemic stroke 20 (2%
TIA 11 (1%
Combined survival/stroke 40 (3%
Values are presented as n, n (%), or mean  SD.
Abbreviations as in Table 1.
Independent Predictors of AF ProgressionResulti g From Mul ivariate Logistic RegressionTable 4 Ind pendent Predictors of AF ProgrResulting From Multivariate Logisti
OR 9
History of heart failure 2.22 1.5
Hypertension 1.52 1.0
Chronic obstructive pulmonary disease 1.51 0.9
History of stroke or TIA 2.02 1.2
Age 75 yrs 1.57 1.0CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.inally, patients who progressed to more sustained forms of
F underwent more electrical cardioversions, were more
ften admitted to the hospital for a cardiovascular problem,
nd had more often a stroke or TIA during the 1 year of
ollow-up. We found no significant differences in pharma-
ological cardioversions between both groups.
The multivariate logistic regression regarding factors asso-
iated with AF progression after 1 year of follow-up is
resented in Table 4. A history of heart failure, hypertension,
OPD, and stroke or TIA and age older than 75 years were
he only independent factors associated with AF progression.
o significant interactions were found between these variables.
sing the regression coefficient as a benchmark, we deter-
ined the relative contribution of each factor to the prediction
f AF progression. This resulted in the HATCH score rule:
 (hypertension)  1  (age 75 years)  2  (stroke or
IA)  1  (COPD)  2  (heart failure).
No AF Progression AF Progression p Value
1,041 (85%) 178 (15%)
280 (29%) 86 (52%) 0.001
16 (2%) 6 (3%) 0.118
107 (10%) 0
860 (83%) 0
0 81 (46%)
0 97 (54%)
74 (7%) 0
419 (50%) 104 (71%) 0.001
217 (22%) 38 (24%) 0.534
0.4  1.3 0.5  1.0 0.847
122 (13%) 39 (26%) 0.001
0.2  0.7 0.4  0.8 0.009
57 (6%) 4 (2%) 0.065
57 (6%) 15 (8%) 0.168
12 (1%) 5 (3%) 0.091
34 (3%) 10 (6%) 0.130
20 (2%) 11 (6%) 0.003
12 (1%) 8 (5%) 0.005
8 (1%) 3 (2%) 0.212
27 (3%) 13 (7%) 0.005
lysisn
ression Analysis
Regression Coefficient p Value Score
2 0.80 0.001 2
0 0.42 0.024 1
9 0.41 0.088 1
1 0.71 0.007 2
0 0.45 0.024 1nts
%)
)
)
%)
)
)
)
%)
%)
.3
%)
.7
)
)
)
)
)
)
)
)Anaessio
c Reg
5% CI
4–3.2
5–2.2
5–2.3
4–3.3
7–2.3
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February 23, 2010:725–31 Progression From Paroxysmal to Persistent AFBecause of its plausible preventive effect on AF progres-
ion, we repeated the logistic regression including antiar-
hythmic drugs. However, antiarrhythmic drugs were not
resent in the final logistic regression model resulting from
his analysis. The final model contained the same variables
s the initial analysis excluding antiarrhythmic drugs (data
ot shown). We also excluded first-detected AF patients
ho underwent a pharmacological cardioversion in a sepa-
ate analysis (data not shown) because these patients could
ave a more advanced electrophysiological substrate than
ure paroxysmal AF patients. However, this did not alter
he results significantly.
Nearly 50% of the patients with paroxysmal AF and a
ATCH score of 6 or 7 had AF progression after 1 year
ompared with only 6% of the patients with a HATCH
core of 0. The percentages of AF progression in patients
ith a HATCH score of 0 through 7 are presented in
igure 1. With increasing HATCH score, the proportion of
atients with AF progression during follow-up increases.
The receiver-operator characteristic curve to discriminate
ndividuals who will or will not have AF progression during
ollow-up based on their HATCH score is shown in Figure 2.
he area under the curve (AUC) is 0.675 (95% confidence
nterval: 0.632 to 0.718, p  0.001). The predictive value
f the HATCH score is higher than all other indepen-
ent predictors of AF progression individually: heart failure
AUC  0.599), hypertension (AUC  0.564), COPD
AUC  0.542), stroke or TIA (AUC  0.545), and age
AUC 0.561). The AUC of the HATCH score was slightly
igher compared with the CHADS2 score (difference: 0.02
95% confidence interval: 0.00 to 0.04); p  0.0576).
We classified patients into 4 groups based on their
ATCH score. The percentages of AF progression for each
Figure 1 Prevalence of the Different HATCH Scores and Inciden
The number of patients for each HATCH score is represented by the blue bars.
HATCH score is represented by the green line.roup are presented in Figure 3. This figure demonstrates
hat with increasing score, the percentage of AF progression
uring follow-up increases as well.
iscussion
he present study is the largest study evaluating clinical
orrelates of AF progression. It provides a unique insight
nto the characteristics and prognosis of patients with
rogression from paroxysmal to more sustained forms of
f Progression
ercentage of atrial fibrillation (AF) progression after 1 year of follow-up per
Figure 2 Predictive Ability of the HATCH Score
The receiver-operator characteristic curve for the prediction
of clinical atrial fibrillation type progression using the HATCH score.ce o
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Progression From Paroxysmal to Persistent AF February 23, 2010:725–31F. Nearly 15% of the patients with paroxysmal AF
ncluded in this study progressed to persistent or permanent
F after 1 year of follow-up, despite the fact that more
ffort was made to obtain sinus rhythm in this group. In
ddition, patients with progression had more adverse car-
iovascular events and were more often admitted in the
ospital. Heart failure, previous stroke or TIA, COPD,
ypertension, and age were independent predictors of AF
rogression. Considering the nature of these factors and in
iew of the fact that they are associated with future
ardiovascular events, one may conjecture that structural
ather than electrical remodeling of the atria is involved in
F progression. Underlying diseases might cause chronic
tretch and atrial dilation, which seem to be important
timuli for chronic atrial structural remodeling (cellular
ypertrophy, fibroblast proliferation, and tissue fibrosis),
hich enables maintenance of AF (8). It is likely that
tructural atrial remodeling leading to atrial pathology
nables the development of cardiovascular events, which
ight explain the relatively high stroke rate among the
atients with AF progression in our survey. In addition,
ecent studies showed that patients with a higher AF
urden, which is the case in patients demonstrating AF
rogression, are more prone to have a stroke (9).
Based on the predictors of AF progression, we developed
risk stratification rule to estimate the probability of AF
rogression in patients with paroxysmal AF: the HATCH
core. This score enables the detection of patients in whom
ore sustained forms of AF are likely to develop in the near
uture. Previous studies showed that the presence of under-
ying heart disease is associated with poor outcome of
hythm control therapy (10). However, these patients are
ore likely to have AF progression. In the same way, our
ata suggest that the potential preventive effect of antiar-
hythmic drugs on AF progression was outperformed by the
romoting effect of underlying heart disease and age, as
epresented by the HATCH parameters. Therefore, it
Figure 3 Incidence of AF Progression
The 1-year incidence of atrial fibrillation (AF) progression per HATCH score.
The HATCH score is divided into 4 categories that could be clinically relevant.eems very important to identify patients that are likely to irogress to persistent AF beforehand to avoid needless
hythm control therapy. This holds even more because AF
rogression may be associated with major events that are
asily enhanced by rhythm control drugs known for their
otential to induce proarrhythmia, heart failure, and atrio-
entricular block. In our study, relatively low numbers of
eta-blockers were prescribed in patients with heart failure
nd coronary artery disease. We hypothesized that this is
robably the result of the use antiarrhythmic drugs in our
atients. Many antiarrhythmic drugs such as amiodarone,
otalol, and propafenone have beta-blocking properties.
radycardia might result when these antiarrhythmic drugs
re prescribed together with a beta-blocker. Our results
uggest that if a high HATCH score is found, clinicians
hould focus on rate control and upstream therapy rather
han rhythm control therapy. Several studies investigating
F progression have been published in the past (5,11–13).
he rate of AF progression described in these studies varied
etween 8% (4) and 22% (14) after 1 year of follow-up,
epending on the rhythm-monitoring methods used. Various
actors were associated with AF progression: valvular disease,
lcohol consumption, age, left atrial dimension and amount of
trial enlargement over time, stroke, and heart failure. How-
ver, correction for possible confounders was not always per-
ormed, and the currently available risk stratification parame-
ers resulting from these studies have limited the predictive
alue in individual patients. Our findings suggest that combin-
ng several independent predictors of AF progression into a
alanced rule outperforms all the previously known predictors
or the development of sustained AF.
linical implications. The HATCH score in daily prac-
ice could guide the physician in the clinical decision-
aking process. First, patients with a high HATCH score
hould be monitored more frequently because they are prone
o the development of cardiovascular events. In addition,
ne could hypothesize that the HATCH score may be used
or early selection of patients for rhythm control therapy in
n effort to prevent disease progression. Conversely, poten-
ially harmful drugs and interventions including cardiover-
ion and ablation may be avoided in patients with a high
ATCH score. Obviously, further studies are needed to
onfirm these hypotheses and show the clinical value of the
ATCH score when implemented in clinical practice.
tudy limitations. We performed a subgroup analysis of the
HS. As a result, our data should be interpreted with care.
ollow-up regarding rhythm status was unavailable for approx-
mately 31% of the patients with first detected or paroxysmal
F at baseline. Patients with unknown rhythm status had
ore often underlying heart disease and a higher HATCH
core (1.8 vs. 1.5) compared with patients with a known
hythm status at follow-up (additional data not shown). This
ay have led to an underestimation of the incidence of AF
rogression. Conversely, this does not, in our view, reduce the
redictive capacity of the HATCH score.
Considering the relatively low use of beta-blockers, ACEnhibitors, and angiotensin-receptor blockers, the patients
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February 23, 2010:725–31 Progression From Paroxysmal to Persistent AFncluded in the present analysis may have been undertreated,
specially the patients concomitantly having coronary artery
isease and heart failure (15). Future studies may show that
rogression factors other than the HATCH score are
mportant in AF patients fully managed according to all the
uidelines pertinent to their various underlying diseases.
he definition of AF progression that we selected is
rbitrary. In clinical practice, it is extremely difficult to
obustly determine the progression from persistent to per-
anent AF because a firm end point is lacking. However,
e believe that our definition reflects the pathophysiological
tage of AF severity. This is supported by the direct or
ndirect relationship between AF progression as defined and
linical outcomes such as hospital admissions and major
dverse cardiovascular events.
The predictive value of the HATCH score was not
awless. In addition, the score should be validated in
nother population of patients with AF before it can be
pplied in clinical practice.
onclusions
his is the largest study exploring the characteristics and
utcome of patients with AF progression. A substantial
umber of patients progress to sustained AF within 1 year.
he clinical outcome of these patients with regard to
ospital admissions and major adverse cardiovascular events
as worse compared with patients demonstrating no AF
rogression. Heart failure, previous stroke or TIA, COPD,
ypertension, and age were independent predictors of AF
rogression. Based on these parameters, we developed the
ATCH score, which enhances detection of patients in
hom more sustained forms of AF are likely to develop in
he near future.
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epartment of Cardiology, Maastricht University Medical Centre,
.O. Box 5800, 6202 AZ Maastricht, the Netherlands. E-mail:
ees.de.vos@mumc.nl.
EFERENCES
1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic
features of chronic atrial fibrillation: the Framingham study. N Engl
J Med 1982;306:1018–22. p2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation—
executive summary: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and
the European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Revise the 2001 Guidelines for the
Management of Patients With Atrial Fibrillation). J Am Coll Cardiol
2006;48:854–906.
3. Levy S, Maarek M, Coumel P, et al. Characterization of different
subsets of atrial fibrillation in general practice in France: the ALFA
study. The College of French Cardiologists. Circulation 1999;99:
3028–35.
4. Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic
atrial fibrillation after the initial diagnosis of paroxysmal atrial fibril-
lation: results from the Canadian Registry of Atrial Fibrillation. Am
Heart J 2005;149:489–96.
5. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease
progression, and treatment of atrial fibrillation patients during 1 year:
follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J.
2008;29:1181–9.
6. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation manage-
ment: a prospective survey in ESC member countries: the Euro Heart
Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422–34.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW,
Radford MJ. Validation of clinical classification schemes for predicting
stroke: results from the National Registry of Atrial Fibrillation. JAMA
2001;285:2864–70.
8. Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U.
Mechanisms of perpetuation of atrial fibrillation in chronically dilated
atria. Prog Biophyss Mol Biol 2008;97:435–51.
9. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial
fibrillation detected by continuous monitoring: crucial implications for
the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009;
20:241–8.
0. Shah AN, Mittal S, Sichrovsky TC, et al. Long-term outcome
following successful pulmonary vein isolation: pattern and prediction
of very late recurrence. J Cardiovasc Electrophysiol 2008;19:661–7.
1. Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA.
Predictors and prognosis of paroxysmal atrial fibrillation in general
practice in the UK. BMC Cardiovasc Disord 2005;5:20.
2. Parkash R, Green MS, Kerr CR, et al. The association of left atrial
size and occurrence of atrial fibrillation: a prospective cohort study
from the Canadian Registry of Atrial Fibrillation. Am Heart J
2004;148:649–54.
3. Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature
of paroxysmal atrial fibrillation. Observations from a 14-year follow-up
study. Circ J 2004;68:568–72.
4. Gianfranchi L, Brignole M, Menozzi C, Lolli G, Bottoni N. Deter-
minants of development of permanent atrial fibrillation and its
treatment. Europace 1999;1:35–9.
5. Nieuwlaat R, Eurlings LW, Cleland JG, et al. Atrial fibrillation and
heart failure in cardiology practice: reciprocal impact and combined
management from the perspective of atrial fibrillation: results of the
Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009;53:
1690–8.
ey Words: atrial fibrillation y epidemiology y prediction y
rogression y prognosis.
